PMEL and uveal melanoma: More recently, tebentafusp, a gp100 peptide-HLA-A2 × CD3 T-cell engager, has been approved both in the USA and Europe for the treatment of uveal melanoma and malignant melanoma, opening new perspectives in TSA-targeting approaches [210].